Ajulemic acid - Corbus Pharmaceuticals

Drug Profile

Ajulemic acid - Corbus Pharmaceuticals

Alternative Names: Ajulemic acid; Anabasum; CPL-7075; CT-3; DMH-11C; HU-239; IP-751; JBT-101; Resunab

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Massachusetts Medical School
  • Developer Cervelo Pharmaceuticals; Corbus Pharmaceuticals; Indevus Pharmaceuticals; National Institute of Arthritis and Musculoskeletal and Skin Diseases; University of Erlangen-Nuremberg; University of Pennsylvania; University of Siena
  • Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Antirheumatics; Cannabinoids; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 modulators; Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis; Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Interstitial cystitis

Highest Development Phases

  • Phase II Cystic fibrosis; Dermatomyositis; Systemic scleroderma
  • Phase I Inflammation
  • Preclinical Pulmonary fibrosis
  • Discontinued Interstitial cystitis; Muscle spasticity; Neuropathic pain; Pain; Poisoning

Most Recent Events

  • 27 Nov 2017 The USPTO issues US Patent No. 9 820 964 for the use of pharmaceutical compositions comprising ajulemic acid in multiple fibrotic diseases
  • 06 Nov 2017 Updated efficacy and adverse events data from an extension study of a phase II trial in Systemic scleroderma released by Corbus Pharmaceuticals
  • 31 Oct 2017 Corbus Pharmaceuticals has patent protection for the use of pharmaceutical compositions comprising ajulemic acid in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top